Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros

Base de dados
País/Região como assunto
Ano de publicação
Tipo de documento
País de afiliação
Intervalo de ano de publicação
1.
J Pak Med Assoc ; 69(Suppl 2)(6): S57-S63, 2019 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-31369535

RESUMO

OBJECTIVE: Eczema, a chronic dermatologic disease, has been recognized as an economic burden in publications all over the word but only minimally as such in Vietnam. The aim of this prospective study was to quantify the financial hardships and impairments suffered by eczema patients. METHODS: This cross-sectional prevalence-based study involved 136 patients, whose conditions were classified into three severity levels on the basis of the medications that they were prescribed. Prescription therapy was administered for a month, after which there was patient-oriented assessment of effectiveness. The work productivity and activity impairment (WPAI) questionnaire was used to evaluate productivity loss, which was expressed in percentage form. Bootstrapping was conducted to determine continuous variables and demographybased differences in cost values among the patient groups. RESULTS: For the month-long treatment, each eczema patient needed an average of US$68.1 (range: US$56.2- US$81.5) with the highest proportion being spent on cosmetic treatments. There is noticeable difference between groups among which patients' symptoms demonstrated in distinct levels. The estimates indicated that eczema resulted in 27.8% and 23.1% impairments in work and daily activities, respectively. CONCLUSIONS: The aggravation of disease symptoms can increase the direct costs borne by eczema patients. A decrease in productivity, which is one of the most serious consequences of the condition, should be paid adequate attention to minimize burdens to society.


Assuntos
Dermatite Atópica/economia , Eficiência , Desempenho Profissional/economia , Absenteísmo , Corticosteroides/economia , Corticosteroides/uso terapêutico , Adulto , Idoso , Inibidores de Calcineurina/economia , Inibidores de Calcineurina/uso terapêutico , Cosméticos/economia , Cosméticos/uso terapêutico , Estudos Transversais , Dermatite Atópica/terapia , Fármacos Dermatológicos/economia , Fármacos Dermatológicos/uso terapêutico , Suplementos Nutricionais/economia , Custos de Medicamentos , Emolientes/economia , Emolientes/uso terapêutico , Feminino , Seguimentos , Custos de Cuidados de Saúde , Antagonistas dos Receptores Histamínicos/economia , Antagonistas dos Receptores Histamínicos/uso terapêutico , Humanos , Masculino , Pessoa de Meia-Idade , Índice de Gravidade de Doença , Higiene da Pele , Vietnã
2.
Eur Ann Allergy Clin Immunol ; 36(9): 333-6, 2004 Nov.
Artigo em Francês | MEDLINE | ID: mdl-15633370

RESUMO

AIMS: To measure evolution and cost consumption of anti-allergic medicines during ragweed pollen-period, geographic trend in the locations of anti-allergic consumers. Ragweed is highly spread in Rhone Alps. METHODS: We measured the ratio: number of boxes of anti-allergic medicines per one thousand patients between 6 and 64 years, refunded by twelve local health offices in the Rhone Alps area. We obtained statistical mapping for consumers of triamcinolone, we analysed in the relation to weakly ragweed pollen figures. RESULTS: Four geographic areas showed high increases of antihistaminic consumption from the middle of august to the end of september during the four years studied. A threefold increase of consumption of antihistaminic medicines, anti-allergic eye-drops and anti-allergic nasals topics was observed during ragweed pollen-period (week 33 to week 40). Antihistaminic consumption ratios increased in relation with ragweed pollen-period This study demonstrated that the anti-allergic medicines consumption reflected the image of ragweed allergy. This sanitary feature is easily obtained from the refunded databases of Medical Insurance.


Assuntos
Alérgenos/efeitos adversos , Ambrosia/efeitos adversos , Antialérgicos/uso terapêutico , Pólen/efeitos adversos , Rinite Alérgica Sazonal/epidemiologia , Administração Tópica , Adolescente , Adulto , Alérgenos/análise , Antialérgicos/economia , Criança , Custos de Medicamentos/estatística & dados numéricos , Uso de Medicamentos/estatística & dados numéricos , Feminino , França/epidemiologia , Antagonistas dos Receptores Histamínicos/economia , Antagonistas dos Receptores Histamínicos/uso terapêutico , Humanos , Injeções , Reembolso de Seguro de Saúde/estatística & dados numéricos , Masculino , Pessoa de Meia-Idade , Soluções Oftálmicas , Rinite Alérgica Sazonal/tratamento farmacológico , Rinite Alérgica Sazonal/economia , Estações do Ano , Triancinolona/administração & dosagem , Triancinolona/economia , Triancinolona/uso terapêutico
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA